The Rundown Novo Nordisk Wins FDA Approval for Weight-Loss Pill, Alphabet Buys Clean Energy Provider
Dec 23, 2025
Gold and silver prices soar as investors hedge against future uncertainty. Novo Nordisk celebrates FDA approval for its weight-loss pill, WeGovie, creating waves in the market. Google enhances its clean energy portfolio by acquiring a renewable energy firm for $4.75 billion, aiming to support AI growth. Meanwhile, U.S. drone manufacturers thrive after a ban on foreign competitors, and Johnson & Johnson faces a $1.5 billion verdict related to its baby powder. All this and more keeps the financial landscape buzzing!
AI Snips
Chapters
Transcript
Episode notes
Precious Metals Rally Amid Calm Markets
- Gold and silver hit record highs even as stocks rally, signalling parallel demand for hedges.
- Investors expect more 2026 rate cuts and central bank buying, which boosts non-yielding metals.
First GLP‑1 Pill Could Expand Market
- Novo Nordisk gained FDA approval for the first GLP-1 weight-loss pill, WeGovie, expanding access beyond injections.
- Pills cost less to produce and Novo plans a $149/month cash price to broaden adoption.
Temporary Win For Novo Amid Lilly Competition
- Novo's pill arrival may help reverse its market share losses to Eli Lilly, but Lilly's pill could arrive in early 2026.
- The advantage may be temporary as competition from Lilly looms.